RegulatoryCompany release

Cumberland to file ifetroban NDA for Duchenne cardiomyopathy under FDA rolling submission

🇺🇸 Cumberland Pharmaceuticals Inc (CPIX) · Mon 16 Nov 2026

After a pre-NDA meeting, FDA agreed that Cumberland can submit its application for ifetroban in stages, although the evidence package differs from earlier agency suggestions.

Cumberland Pharmaceuticals has said it intends to submit a new drug application to the US Food and Drug Administration for ifetroban, proposed name DYSCORBAN, in cardiomyopathy associated with Duchenne muscular dystrophy. The company made the announcement on 26 October 2026.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Company's press release (SEC filing): Cumberland Pharmaceuticals Inc ↗

Article written by VigiEye from the official source (Cumberland Pharmaceuticals Inc). Claims are the company's own. AI-assisted; check the source before acting.

More Regulatory All →